| Kimberly A Dever, MD | |
|
90 Libbey Parkway, Suite 105, S Weymouth, MA 02189 | |
| (339) 201-4120 | |
| (781) 545-8117 |
| Full Name | Kimberly A Dever |
|---|---|
| Gender | Female |
| Speciality | Obstetrics & Gynecology |
| Location | 90 Libbey Parkway, S Weymouth, Massachusetts |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265433973 | NPI | - | NPPES |
| 3207561 | Medicaid | MA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 78939 (Massachusetts) | Primary |
| Entity Name | Coastal Medical Associates |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932175684 PECOS PAC ID: 7113029257 Enrollment ID: O20070221000057 |
News Archive
Emergent BioSolutions Inc. announced today that it has signed a contract valued at up to $107 million with the Office of the Biomedical Advanced Research and Development Authority (BARDA) of the Department of Health and Human Services (HHS), to develop and obtain regulatory approval for large-scale manufacturing of BioThrax® (Anthrax Vaccine Adsorbed) in Building 55. Building 55 is the company's large-scale state-of-the-art vaccine manufacturing facility in Lansing, Michigan.
Molecular Detection Inc. (MDI), a company developing Detect-Ready™ tests designed to increase the speed and accuracy of infectious disease diagnosis, and life sciences and diagnostics distributor Westburg BV today announced that they have entered into an exclusive agreement for distribution of MDI's Detect-Ready MRSA panel in the Benelux region.
As fall and winter sports are in full swing, youth athletics will see a rise in injuries. Tens of millions of children and teens participate in organized sports, and more than 3.5 million sports injuries occur every year.
Researchers from King's College London have now found how the chemical cannabidiol or CBD from cannabis can reduce the abnormal brain activity in patients who are at risk of psychosis. The study was published in the latest issue of the journal JAMA Psychiatry.
XenoPort, Inc. announced today that it has initiated a Phase 2 clinical trial of XP23829, its proprietary investigational next-generation fumaric acid product candidate. The trial is a multi-center, randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of XP23829 as a potential treatment of patients with moderate-to-severe chronic plaque-type psoriasis.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kimberly A Dever, MD Po Box 188, S Weymouth, MA 02190 Ph: (339) 201-4120 | Kimberly A Dever, MD 90 Libbey Parkway, Suite 105, S Weymouth, MA 02189 Ph: (339) 201-4120 |
News Archive
Emergent BioSolutions Inc. announced today that it has signed a contract valued at up to $107 million with the Office of the Biomedical Advanced Research and Development Authority (BARDA) of the Department of Health and Human Services (HHS), to develop and obtain regulatory approval for large-scale manufacturing of BioThrax® (Anthrax Vaccine Adsorbed) in Building 55. Building 55 is the company's large-scale state-of-the-art vaccine manufacturing facility in Lansing, Michigan.
Molecular Detection Inc. (MDI), a company developing Detect-Ready™ tests designed to increase the speed and accuracy of infectious disease diagnosis, and life sciences and diagnostics distributor Westburg BV today announced that they have entered into an exclusive agreement for distribution of MDI's Detect-Ready MRSA panel in the Benelux region.
As fall and winter sports are in full swing, youth athletics will see a rise in injuries. Tens of millions of children and teens participate in organized sports, and more than 3.5 million sports injuries occur every year.
Researchers from King's College London have now found how the chemical cannabidiol or CBD from cannabis can reduce the abnormal brain activity in patients who are at risk of psychosis. The study was published in the latest issue of the journal JAMA Psychiatry.
XenoPort, Inc. announced today that it has initiated a Phase 2 clinical trial of XP23829, its proprietary investigational next-generation fumaric acid product candidate. The trial is a multi-center, randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of XP23829 as a potential treatment of patients with moderate-to-severe chronic plaque-type psoriasis.
› Verified 7 days ago
Dr. Christine Dailey Hirsemann, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 90 Libbey Parkway, Suite 105, S Weymouth, MA 02189 Phone: 339-201-4120 Fax: 781-545-8117 | |
Dr. Karen Mary Toujouse, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 90 Libbey Parkway, Suite 105, S Weymouth, MA 02189 Phone: 339-201-4120 Fax: 781-545-8117 | |
Dr. Julianne Arena, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 90 Libbey Parkway, Suite 105, S Weymouth, MA 02189 Phone: 339-201-4120 Fax: 781-545-8117 | |
Dr. Darlyne A Johnson, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 90 Libbey Parkway, Suite 105, S Weymouth, MA 02189 Phone: 339-201-4120 Fax: 781-545-8117 | |
Carolyn Martha Mcnulty, D.O. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 90 Libbey Parkway, Suite 105, S Weymouth, MA 02189 Phone: 339-201-4120 Fax: 781-545-8117 |